Look­ing to top­ple Pfiz­er's Pre­vnar 13 dy­nasty, Mer­ck claims an­oth­er win for its 'break­through' pneu­mo­coc­cal con­ju­gate vac­cine

Three months af­ter win­ning the FDA’s break­through ther­a­py des­ig­na­tion for its big­ger/bet­ter pneu­mo­coc­cal con­ju­gate vac­cine can­di­date aimed at top­pling Pfiz­er’s Pre­vnar 13 megablock­buster best­seller …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER